In its Phase 2 trial of PH-10 for atopic dermatitis (???eczema???), preliminary data from the first 18 subjects indicated that 94% of subjects had improvement in the Eczema Area Severity Index (EASI) during four weeks of treatment. Subjects applied PH-10 daily for up to four weeks to skin areas affected by atopic dermatitis, with response observed weekly throughout this treatment phase and for one month after the end of this period. As in the psoriasis study, the treatments were generally well tolerated with no significant safety issues identified.

Dees noted, ???These data are consistent with earlier observations from Phase 1 testing of PH-10 for psoriasis. The potential efficacy, combined with the low incidence of side effects, is very encouraging.???

According to the National Institutes of Health, as many as 7.5 million Americans, approximately 2.2 percent of the population, have psoriasis. The National Psoriasis Foundation reports that approximately 125 million people worldwide, 2 to 3 percent of the total population have psoriasis. It also reports that total direct and indirect health care costs of psoriasis for patients are approximately $11.25 billion annually.

Source Provectus Pharmaceuticals, Inc.